Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$76,759.00-1.92%ETH$2,449.71-0.78%GOLD$4,364.00-0.98%OIL$103.08+0.59%
Smart Investors Daily
CA

NASDAQ · CADL

Candel Therapeutics, Inc.

Healthcare · Biotechnology

$12.17

Down-$0.84 (-6.90%)

Updated Sep 11, 2026, 12:41 AM

SID Score

6.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
355.76M
P/E ratio
-30.96
Dividend yield
0.00%
52-week range
$4.44 – $14.00
Volume
661.25K
Avg. volume
778.62K

Price performance

CADL price history

1M range · 19 trading sessions · Daily adjusted prices

CADL closed at $12.17 after 19 trading sessions, up 3.14% for the selected period.

Last close
$12.17
Period change
+3.14%
Period low
$11.72
Period high
$13.75
Daily close
View OHLC price history
CADL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 9, 2026$12.52$12.78$12.13$12.17661.25K
Sep 8, 2026$12.57$12.8458$12.02$12.601M
Sep 4, 2026$12.91$13.05$12.76$12.78535.82K
Sep 3, 2026$13.21$13.28$12.73$12.97628.31K
Sep 2, 2026$12.81$13.4099$12.6713$13.20807.85K
Sep 1, 2026$12.93$13.035$12.602$12.85935.64K
Aug 31, 2026$13.02$13.22$12.63$13.07895.01K
Aug 28, 2026$13.635$13.7999$12.88$13.071.24M
Aug 27, 2026$13.26$14.00$13.20$13.751.19M
Aug 26, 2026$13.60$13.85$13.19$13.28978K
Aug 25, 2026$13.09$13.95$12.9723$13.601.34M
Aug 24, 2026$12.99$12.99$12.40$12.86959.09K
Aug 21, 2026$12.52$13.255$12.38$13.131.34M
Aug 20, 2026$13.23$13.38$12.33$12.351.54M
Aug 19, 2026$12.42$13.82$12.2795$13.502.38M
Aug 18, 2026$12.03$12.15$11.77$12.05786.87K
Aug 17, 2026$11.49$12.485$11.11$12.162.16M
Aug 14, 2026$11.85$11.945$11.04$11.722.07M
Aug 13, 2026$10.85$11.87$10.475$11.802.15M

Latest CADL news

The latest Smart Investors Daily articles mentioning CADL.

Stock researchCompany · Overview

CADL research

Overview

Company profile and research snapshot.

Company profile

Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$15.00
Implied upside
—
Analysts
14
CADL recent ratings
DateFirmRatingTarget
Aug 14, 2026B of A SecuritiesNeutral—
Aug 13, 2026HC Wainwright & Co.Buy—
Jul 13, 2026StifelBuy—
Apr 20, 2026Cantor FitzgeraldOverweight—
Mar 18, 2026CitigroupBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 1, 2026

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEEDHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on August 31, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to two new employees, stock options to purchase an aggregate of 31,400 shares of the Company’s common stock, with a pe

Yahoo · Aug 26, 2026

Oncolytic Virus Cancer Therapy Market Expected to Expand Rapidly During the Forecast Period (2026-2036) Amid Rising Investments in Next-Generation Cancer Treatments| DelveInsight

DelveInsight's Oncolytic Virus Cancer Therapy Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Melanoma, Biliary Tract Cancer, Head and Neck Cancer, Pancreatic Cancer, NSCLC, Hepatocellular Carcinoma, Breast Cancer, Prostate Cancer, Brain Cancer, Bladder Cancer, Ovarian Cancer, and others. The selected indications are based on

Yahoo · Aug 26, 2026

Candel Therapeutics to Present at September Investor Conferences

NEEDHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and Chief Executive Officer, will participate in analyst-led fireside discussions and one-on-one meetings at upcoming investor conferences in September 2026. Ke

Yahoo · Aug 20, 2026

Candel Therapeutics (CADL) Faces Bigger Losses As Its Valuation Still Looks Pricey

Candel Therapeutics (CADL) drew attention after reporting second quarter 2026 results that showed a net loss of US$38.91 million, compared with US$4.8 million a year earlier, indicating increased operating pressures. See our latest analysis for Candel Therapeutics. The latest earnings release landed alongside sharp share price gains for Candel Therapeutics, with a 1-day share price return of 12.03% and a 90-day share price return of 70.24%. The 3-year total shareholder return is also very...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By